Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology

There is a plethora of new anti-angiogenic drugs in development. The potential to block tumor growth and metastases by angiogenesis inhibition represents an intriguing therapeutic strategy for the treatment of cancer and never before have we seen as many anti-angiogenic drugs in clinical trials.

This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you.

First, BioSeeker has surveyed anti-angiogenic drugs in oncology and identified 108 drug targets, belonging to 123drugs. This report, Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new anti-angiogenic drugs in oncology.

In the report, BioSeeker reports on 88 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 123 anti-angiogenic drugs designed for the treatment of 44 different cancer indications. The highest degree of distinctiveness among anti-angiogenic drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of anti-angiogenic drugs. No less than 162 protein-protein interactions were recognized among and between 86 of the 108 included anti-angiogenic drug targets.

Why You Should Own Your Own Copy of this Report:

* 230+ pages, with almost a hundred different tables and figures. Includes more than 1,500 active links to related resources on the Internet

* 123 anti-angiogenic drugs, under development by 90 investigators, are included, covering more than 361 developmental projects in cancer

* 108 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other anti-angiogenic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.

* Unique 231 drug-protein target interactome analysis

* Unique drug target combination breakdown into 44 different cancer types

* Covers 88 unique drug target combinations of anti-angiogenic drugs

* 162 protein-protein interactions among and between anti-angiogenic drug targets

* Pathway grouping of anti-angiogenic drug targets

* Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development

* Who are working on sequels to blockbuster drugs

* Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

Pages: 231 March 2008
Table of Contents
Price: $3,800.00 / GBP1,900.00